Pharmaceutical Technology on MSN1d
Macau approves IASO Bio’s multiple myeloma therapyPharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...
A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.
Adam Perry shares the story of his journey discussing his diagnosis, treatment and the importance of early detection.
Triplet therapy with bortezomib, lenalidomide and dexamethasone — a regimen often referred to as VRd — is a current standard ...
Action Month, created, according to the International Myeloma Foundation (IMF), “to draw attention to the disease and inspire ...
A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient ...
This is Allison’s personal multiple myeloma story, and others may be different. Allison is a paid spokesperson for GSK.
During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory ...
Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.
The following is a summary of “Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma ...
Driving Restrictions Beyond 1 Month After CAR-T Therapy Not Needed for All Patients, Researchers Say
Researchers proposed changing the recommendations for universal driving restrictions after CAR T-cell infusion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback